Teva Pharmaceuticals’ big-selling multiple sclerosis drug Copaxone is losing ground in the U.S. thanks to generics, but the medicine was once the company’s primary growth driver. Now, it’s at the center of a lawsuit filed by the state of Israel over alleged unpaid royalties. Israel has sued Teva for $100 million in royalties on the longer-lasting version … Continue reading Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report
The post Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report first appeared on Lawstarz.↧